<p>极地资产管理公司在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度削减了对 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）股票的持仓，减幅为 62.1%。该公司在季度内出售了 35,406 股后，持有 21,594 股该制药公司的股票。极地资产管理公司在 Vertex Pharmaceuticals 的持股在最近一个季度末的价值为 10,469,000 美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Aries Wealth Management 在第一季度购买了价值约 293,000 美元的 Vertex Pharmaceuticals 新头寸。Brighton Jones LLC 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 45.0%。Brighton Jones LLC 现在拥有 6,421 股该制药公司的股票，价值 3,113,000 美元，此前在该期间内又收购了 1,994 股。GAMMA Investing LLC 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 25.1%。GAMMA Investing LLC 现在拥有 5,002 股该制药公司的股票，价值 2,425,000 美元，此前在该期间内又收购了 1,005 股。Stanley Laman Group Ltd.在第一季度购买了价值约 486,000 美元的 Vertex Pharmaceuticals 新头寸。最后，Compagnie Lombard Odier SCmA 在第一季度将其在 Vertex Pharmaceuticals 的股份增加了 31.4%。Compagnie Lombard Odier SCmA 现在拥有 12,565 股该制药公司的股票，价值 6,092,000 美元，此前在该期间内又购买了 3,000 股。目前，90.96% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
<h2>Vertex Pharmaceuticals 股票上涨 0.1%</h2>
<p>VRTX 周五开盘价为 396.93 美元。该公司的市值为 1017.7 亿美元，市盈率为 28.37，贝塔值为 0.44。Vertex Pharmaceuticals Incorporated 的 52 周最低价为 362.50 美元，52 周最高价为 519.88 美元。该公司的 50 日移动平均线为 429.40 美元，200 日移动平均线为 456.95 美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近于 8 月 4 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.52 美元，超出市场共识预期的 4.24 美元，超出幅度为 0.28 美元。该公司季度收入为 29.4 亿美元，而分析师预期为 29 亿美元。Vertex Pharmaceuticals 的股本回报率为 23.91%，净利润率为 31.86%。该公司的收入较去年同期增长了 11.3%。在去年同期，该公司每股收益为（12.83）美元。Vertex Pharmaceuticals 已将其 2025 财年的指引设定为每股收益。股票分析师预计 Vertex Pharmaceuticals Incorporated 在当前财年将发布 15.63 美元的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>VRTX 最近成为几份研究报告的主题。Stifel Nicolaus 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 494.00 美元下调至 455.00 美元，并对该公司给予 “持有” 评级。Wall Street Zen 在 8 月 22 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “买入”。Erste Group Bank 在 5 月 23 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “持有”。Scotiabank 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 442.00 美元下调至 438.00 美元，并对该公司给予 “行业表现” 评级。最后，Guggenheim 在 8 月 6 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 558.00 美元下调至 546.00 美元，并对该公司给予 “买入” 评级。一位股票研究分析师对该股票给予了 “强烈买入” 评级，十三位分析师给予 “买入” 评级，另有十三位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 497.10 美元。</p>
<ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
<p><strong>获取我们关于 Vertex Pharmaceuticals 的最新股票报告</strong></p>
<h2>内部人士买卖</h2>
<p>在相关消息中，董事 Bruce I. Sachs 在 8 月 6 日星期三购买了 5,000 股该公司的股票。该股票的平均购买价格为 389.68 美元，总交易额为 1,948,400.00 美元。完成购买后，该董事直接持有该公司 45,000 股股票，价值 17,535,600 美元。此交易代表其持股增加了 12.50%。该购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。目前，0.20% 的股票由公司内部人士持有。</p>
<h2>关于 Vertex Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票超过 Vertex Pharmaceuticals</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>这里是 Oklo 与其他核创业公司的区别</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>在经济衰退中与这些股息之王一起度过</li>
<li>Daqo New Energy：太阳能垄断企业推出 1 亿美元回购计划</li>
</ul>
<p><strong>想知道其他对冲基金持有 VRTX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>Polar Asset Management Partners Inc. 在第一季度减少了对 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股比例，降幅为 62.1%，目前持有 21,594 股，价值 1,047 万美元。其他机构投资者也调整了他们的持仓，其中 Brighton Jones LLC 和 GAMMA Investing LLC 的增持尤为显著。Vertex 的股票开盘价为 396.93 美元，市值为 1,017.7 亿美元。该公司报告了第二季度每股收益 (EPS) 为 4.52 美元，超出预期，并已设定 2025 财年的每股收益指导。分析师对该股的评级不一，平均目标价为 497.10 美元</p>

<p>Polar Asset Management Partners Inc. trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 62.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,594 shares of the pharmaceutical company's stock after selling 35,406 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Vertex Pharmaceuticals were worth $10,469,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>极地资产管理公司在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度削减了对 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）股票的持仓，减幅为 62.1%。该公司在季度内出售了 35,406 股后，持有 21,594 股该制药公司的股票。极地资产管理公司在 Vertex Pharmaceuticals 的持股在最近一个季度末的价值为 10,469,000 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. Aries Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $293,000. Brighton Jones LLC boosted its holdings in Vertex Pharmaceuticals by 45.0% during the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock valued at $3,113,000 after acquiring an additional 1,994 shares during the period. GAMMA Investing LLC boosted its holdings in Vertex Pharmaceuticals by 25.1% during the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock valued at $2,425,000 after acquiring an additional 1,005 shares during the period. Stanley Laman Group Ltd. purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $486,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in shares of Vertex Pharmaceuticals by 31.4% in the 1st quarter. Compagnie Lombard Odier SCmA now owns 12,565 shares of the pharmaceutical company's stock valued at $6,092,000 after buying an additional 3,000 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Aries Wealth Management 在第一季度购买了价值约 293,000 美元的 Vertex Pharmaceuticals 新头寸。Brighton Jones LLC 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 45.0%。Brighton Jones LLC 现在拥有 6,421 股该制药公司的股票，价值 3,113,000 美元，此前在该期间内又收购了 1,994 股。GAMMA Investing LLC 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 25.1%。GAMMA Investing LLC 现在拥有 5,002 股该制药公司的股票，价值 2,425,000 美元，此前在该期间内又收购了 1,005 股。Stanley Laman Group Ltd.在第一季度购买了价值约 486,000 美元的 Vertex Pharmaceuticals 新头寸。最后，Compagnie Lombard Odier SCmA 在第一季度将其在 Vertex Pharmaceuticals 的股份增加了 31.4%。Compagnie Lombard Odier SCmA 现在拥有 12,565 股该制药公司的股票，价值 6,092,000 美元，此前在该期间内又购买了 3,000 股。目前，90.96% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
</div><h2>Vertex Pharmaceuticals Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票上涨 0.1%</h2>
</div><p>VRTX opened at $396.93 on Friday. The firm has a market cap of $101.77 billion, a price-to-earnings ratio of 28.37 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The business's 50 day moving average is $429.40 and its two-hundred day moving average is $456.95.</p>
<div class="lb-trans"><p>VRTX 周五开盘价为 396.93 美元。该公司的市值为 1017.7 亿美元，市盈率为 28.37，贝塔值为 0.44。Vertex Pharmaceuticals Incorporated 的 52 周最低价为 362.50 美元，52 周最高价为 519.88 美元。该公司的 50 日移动平均线为 429.40 美元，200 日移动平均线为 456.95 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm's revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近于 8 月 4 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.52 美元，超出市场共识预期的 4.24 美元，超出幅度为 0.28 美元。该公司季度收入为 29.4 亿美元，而分析师预期为 29 亿美元。Vertex Pharmaceuticals 的股本回报率为 23.91%，净利润率为 31.86%。该公司的收入较去年同期增长了 11.3%。在去年同期，该公司每股收益为（12.83）美元。Vertex Pharmaceuticals 已将其 2025 财年的指引设定为每股收益。股票分析师预计 Vertex Pharmaceuticals Incorporated 在当前财年将发布 15.63 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>VRTX has been the subject of several recent research reports. Stifel Nicolaus decreased their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a &#34;hold&#34; rating for the company in a research note on Tuesday, August 5th. Wall Street Zen cut Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, August 22nd. Erste Group Bank cut Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, May 23rd. Scotiabank decreased their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a &#34;sector perform&#34; rating for the company in a research note on Tuesday, August 5th. Finally, Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average price target of $497.10.</p>
<div class="lb-trans"><p>VRTX 最近成为几份研究报告的主题。Stifel Nicolaus 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 494.00 美元下调至 455.00 美元，并对该公司给予 “持有” 评级。Wall Street Zen 在 8 月 22 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “买入”。Erste Group Bank 在 5 月 23 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “持有”。Scotiabank 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 442.00 美元下调至 438.00 美元，并对该公司给予 “行业表现” 评级。最后，Guggenheim 在 8 月 6 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 558.00 美元下调至 546.00 美元，并对该公司给予 “买入” 评级。一位股票研究分析师对该股票给予了 “强烈买入” 评级，十三位分析师给予 “买入” 评级，另有十三位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 497.10 美元。</p>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Vertex Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Bruce I. Sachs 在 8 月 6 日星期三购买了 5,000 股该公司的股票。该股票的平均购买价格为 389.68 美元，总交易额为 1,948,400.00 美元。完成购买后，该董事直接持有该公司 45,000 股股票，价值 17,535,600 美元。此交易代表其持股增加了 12.50%。该购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。目前，0.20% 的股票由公司内部人士持有。</p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Here's What Separates Oklo From the Rest of the Nuclear Startups</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Vertex Pharmaceuticals</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>这里是 Oklo 与其他核创业公司的区别</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>在经济衰退中与这些股息之王一起度过</li>
<li>Daqo New Energy：太阳能垄断企业推出 1 亿美元回购计划</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有 VRTX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Polar Asset Management Partners Inc. 减少了在福泰制药公司 $VRTX 的股票持有量